Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Metagenomi Therapeutics (MGX) Interest & Investment Income (2023 - 2025)

Metagenomi (MGX) has disclosed Interest & Investment Income for 3 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 41.05% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Dec 2025, down 35.67% year-over-year, with the annual reading at $9.5 million for FY2025, 35.67% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $1.9 million at Metagenomi, down from $2.2 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $4.0 million in Q1 2023, with the low at $1.9 million in Q4 2025.
  • Average Interest & Investment Income over 3 years is $3.3 million, with a median of $3.6 million recorded in 2023.
  • The sharpest move saw Interest & Investment Income increased 0.23% in 2024, then plummeted 41.05% in 2025.
  • Over 3 years, Interest & Investment Income stood at $3.6 million in 2023, then decreased by 12.0% to $3.2 million in 2024, then tumbled by 41.05% to $1.9 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $1.9 million, $2.2 million, and $2.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.